Michael Kurowski

1.7k total citations
65 papers, 1.3k citations indexed

About

Michael Kurowski is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Michael Kurowski has authored 65 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Infectious Diseases, 31 papers in Virology and 12 papers in Emergency Medicine. Recurrent topics in Michael Kurowski's work include HIV/AIDS drug development and treatment (40 papers), HIV Research and Treatment (31 papers) and HIV/AIDS Research and Interventions (14 papers). Michael Kurowski is often cited by papers focused on HIV/AIDS drug development and treatment (40 papers), HIV Research and Treatment (31 papers) and HIV/AIDS Research and Interventions (14 papers). Michael Kurowski collaborates with scholars based in Germany, United Kingdom and United States. Michael Kurowski's co-authors include Courtney V. Fletcher, Giorgio Gatti, Rodolphe Garaffo, David Back, Carlo Federico Perno, Marta Boffito, Schlomo Staszewski, Andrew Hill, Andrew Luber and Richard Haubrich and has published in prestigious journals such as Clinical Infectious Diseases, Gut and Brain Research.

In The Last Decade

Michael Kurowski

64 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Kurowski Germany	20	863	590	214	209	163	65	1.3k
Clementina Maria Galluzzo Italy	21	624 0.7×	551 0.9×	158 0.7×	197 0.9×	44 0.3×	76	1.2k
Joseph E. Rower United States	19	797 0.9×	342 0.6×	89 0.4×	341 1.6×	164 1.0×	58	1.3k
Charlotte M. Harvey United States	9	573 0.7×	469 0.8×	116 0.5×	169 0.8×	53 0.3×	9	1.0k
Stephen S. Hwang United States	17	531 0.6×	812 1.4×	47 0.2×	174 0.8×	167 1.0×	38	1.8k
J. Durant France	21	1.3k 1.5×	1.1k 1.9×	250 1.2×	380 1.8×	71 0.4×	91	1.9k
Michael Lamson United States	12	579 0.7×	398 0.7×	114 0.5×	132 0.6×	140 0.9×	25	842
Peter P. Koopmans Netherlands	24	1.5k 1.8×	1.1k 1.8×	731 3.4×	579 2.8×	275 1.7×	54	2.5k
Amanda J. Jenkins United States	18	273 0.3×	147 0.2×	165 0.8×	160 0.8×	73 0.4×	42	1.2k
Evelyn M. Rodriguez United States	15	396 0.5×	139 0.2×	106 0.5×	166 0.8×	245 1.5×	25	1.2k
Jomy George United States	17	357 0.4×	160 0.3×	70 0.3×	313 1.5×	122 0.7×	34	1.1k

Countries citing papers authored by Michael Kurowski

Since Specialization

Citations

This map shows the geographic impact of Michael Kurowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kurowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kurowski more than expected).

Fields of papers citing papers by Michael Kurowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kurowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kurowski. The network helps show where Michael Kurowski may publish in the future.

Co-authorship network of co-authors of Michael Kurowski

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Kurowski. A scholar is included among the top collaborators of Michael Kurowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Kurowski. Michael Kurowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perri, Giovanni Di, Bruce Green, Glynn Morrish, et al.. (2013). Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients. HIV Clinical Trials. 14(3). 92–98. 5 indexed citations

Khaykin, Pavel, Christoph Stephan, Markus Bickel, et al.. (2013). Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment. Therapeutic Drug Monitoring. 36(2). 192–201. 2 indexed citations

Lelyveld, S.F.L. van, Monique Nijhuis, Ingeborg Wilting, et al.. (2010). Therapy Failure following Selection of Enfuvirtide‐Resistant HIV‐1 in Cerebrospinal Fluid. Clinical Infectious Diseases. 50(3). 387–390. 26 indexed citations

Haberl, Annette, Christoph Stephan, Markus Bickel, et al.. (2009). Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. European Journal of Clinical Pharmacology. 66(4). 375–381. 6 indexed citations

Bickel, Markus, Christoph Stephan, Nils von Hentig, et al.. (2009). Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. Journal of Antimicrobial Chemotherapy. 64(6). 1260–1264. 1 indexed citations

Kunz, Andrea, et al.. (2007). Intrapartum Transmission After Mucosal Exposure to HIV Was Not Observed With Single-Dose Nevirapine for Mother and Child. JAIDS Journal of Acquired Immune Deficiency Syndromes. 44(5). 562–565.

Schürmann, Dirk, Hans Wesselmann, Michael Kurowski, Norbert Suttorp, & Petra Reinke. (2007). Kaletra® Single Agent HAART after Intolerance of NRTI- and NNRTI-Containing Regimens Following Kidney Transplantation. Infection. 35(3). 194–196. 1 indexed citations

Gingelmaier, Andrea, Michael Kurowski, R Kästner, et al.. (2006). Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS. 20(13). 1737–1743. 44 indexed citations

Hentig, Nils von, Amina Carlebach, Peter Gute, et al.. (2006). A comparison of the steady‐state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. British Journal of Clinical Pharmacology. 62(5). 552–559. 34 indexed citations

10.

Mauss, S, Stefan Scholten, Eva Wolf, et al.. (2004). A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. HIV Medicine. 5(1). 15–17. 8 indexed citations

11.

Boffito, Marta, Michael Kurowski, Andrew Hill, et al.. (2004). Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS. 18(9). 1291–1297. 62 indexed citations

12.

Kurowski, Michael, Charles Oo, Hugh Wiltshire, & Joanne Barrett. (2004). Oseltamivir Distributes to Influenza Virus Replication Sites in the Middle Ear and Sinuses. Clinical Drug Investigation. 24(1). 49–53. 15 indexed citations

13.

Stephan, Christoph, Nils von Hentig, Irene S. Kourbeti, et al.. (2004). Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS. 18(3). 503–508. 45 indexed citations

14.

Hoffmann, Florian, Michael Kurowski, Hartmut Stocker, et al.. (2004). Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children. AIDS. 18(10). 1473–1475. 3 indexed citations

15.

Kurowski, Michael, et al.. (2003). Pharmacokinetic and tolerability profile of twice‐daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Medicine. 4(2). 94–100. 44 indexed citations

16.

Vaerenbergh, Kristien Van, Thomas Harrer, Jean‐Claude Schmit, et al.. (2002). Initiation of HAART in Drug-Naive HIV Type 1 Patients Prevents Viral Breakthrough for a Median Period of 35.5 Months in 60% of the Patients. AIDS Research and Human Retroviruses. 18(6). 419–426. 18 indexed citations

17.

Back, David, Giorgio Gatti, Courtney V. Fletcher, et al.. (2002). Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 16. S5–S37. 147 indexed citations

18.

Wintergerst, Uwe, et al.. (2000). Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children. AIDS. 14(12). 1866–1868. 11 indexed citations

19.

Loffeld, R. J. L. F., B. F. M. Werdmuller, H Kordecki, et al.. (1996). 1C: Non-gastric diseases related to H. pylori infections. Gut. 39(Suppl 2). A89–A95. 2 indexed citations

20.

Kurowski, Michael & H. Thabe. (1989). The transsynovial distribution of oxaprozin. Inflammation Research. 27(3-4). 458–460. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact